Submit RFI/RFP
Request Consultation
Featured A New Era in Managing Thyroid Eye Disease Patients
For years now Thyroid Eye Disease (TED) has been a struggle to anyone suffering from it, with limited treatment options available on hand & sometimes the need to…
Newsroom
News
153 articles
Featured 
Featured Smarter Pathways to Biosimilars
EMA’s continuous straining efforts to develop & improve biosimilar medicine has been ongoing for decades now. While still maintaining the strict European Union safety standards with the aim…
Featured Fezolinetant risk of liver injury: Minimizing Liver Risk with New Guidelines
Close monitoring of drugs side effects is a necessity, since leaving it un attended can lead to serious complications that on the long run maybe hear to reverse.…
Featured A New Chapter in Research: UK Sets Clinical Trial Standards
A new chapter in in the UK medical research has begun which is more efficient, safer & smarter. With the biggest reform in over two decades. The UK…
Featured EMA Endorses AI Powered Tools Supporting Liver Biopsy Analyses
As AI continues to reshape the future of healthcare, a significant milestone has been achieved. The European Medicines Agency’s (EMA) human medicines committee (CHMP) has granted the first-ever…
Featured Relief in Reach: New Promise to Hemophilia Warriors
For most patients suffering from a chronic illness symptoms is of course their main struggling area, but what sometimes goes un noticed is the frequency & commitment to…
Featured New Approval for Hard-to-Treat HER2-Positive Cancer Tumors
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the use of trastuzumab deruxtecan (Enhertu) for treatment of people with HER-2 positive cancers that has metastasized to…
Featured Expanded Therapeutic use of Kaftrio & Kalydeco in cystic fibrosis patients
Based on recent studies performed by the CHMP which included clinical trials, lab tests, real world evidence studies & bibliographical data. The European Medicines Agency has recommended to…
Featured New Hope for Dystrophic Epidermolysis Bullosa Patients
Dystrophic Epidermolysis Bullosa (DEB) can be a very challenging condition to live with, & with the limited treatment options available on the market, which mainly works on treating…
Featured FDA educational efforts prevented young people from using e-cigarettes
In a single year, FDA educational efforts prevented about 450,000 young people from beginning to use e-cigarettes According to a research co-authored by scientists from the U.S. Food…
Featured Triple combination medication For cystic fibrosis, deutivacaftor, tezacaftor, and vanzacaftor are approved
The Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the triple combination medication deutivacaftor/tezacaftor/vanzacaftor (brand name Alyftrek) to treat cystic fibrosis (CF) in individuals six years of…
Featured Unregulated pharmaceuticals used in advanced therapy present significant health hazards
The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) are warning the public about the risks of unregulated advanced therapy medical products (ATMPs) available to…
Featured mRESVIA RSV vaccine is authorized to protect individuals aged 60 and older
The Medicines and Healthcare Products Regulatory Agency (MHRA) has licensed mRNA respiratory syncytial virus (RSV) vaccine (brand name mRESVIA) to prevent individuals over the age of 60 from…
Featured Prolonged-release opioids
The indication for post-operative pain management has been removed The indication for the management of post-operative pain has been removed from the licenses of all prolonged release opioids,…
Featured The EU has introduced a new clinical trial map
A new clinical trial map is now available on the Clinical Trials Information System (CTIS) public website. The map is intended to offer patients and healthcare professionals with…
Ready to simplify your journey?
Talk to our experts and get tailored solutions to help you stay compliant and move forward with confidence.
Submit RFI/RFP